Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × mCRC × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2161 Neoplasms 1662 Carcinoma, Non-Small-Cell Lung 1435 Prostatic Neoplasms 1206 Colorectal Neoplasms 991 Lung Neoplasms 878 Neoplasm Metastasis 742 Multiple Myeloma 724 Leukemia, Myeloid, Acute 703 Ovarian Neoplasms 614 Pancreatic Neoplasms 609 Melanoma 604 Squamous Cell Carcinoma of Head and Neck 525 Recurrence 517 Carcinoma, Hepatocellular 503 Brain Neoplasms 481 Glioblastoma 458 Stomach Neoplasms 455 Head and Neck Neoplasms 427 Lymphoma 417 Triple Negative Breast Neoplasms 415 Uterine Cervical Neoplasms 400 Precursor Cell Lymphoblastic Leukemia-Lymphoma 392 Carcinoma, Renal Cell 376 Lymphoma, Non-Hodgkin 360 Endometrial Neoplasms 349 Sarcoma 328 Urinary Bladder Neoplasms 324 Colonic Neoplasms 317 Lymphoma, Large B-Cell, Diffuse 314

Interventions

trifluridine tipiracil drug combination 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Jinan Central Hospital

Phase 2 Not yet recruiting

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡